3 results
The primary objective is to demonstrate the superiority of bumetanide (0.5mg BID) oral liquid formulation compared to placebo in the improvement of ASD core symptoms after 6 months of treatment in ASD children aged from 2 to less than 7 years old.
The primary objective is to demonstrate the superiority of bumetanide (0.5mg BID) oral liquid formulation compared to placebo in the improvement of ASD core symptoms after 6 months of treatment in ASD children and adolescents aged from 7 to less…
Primary ObjectiveTo provide a definitive answer regarding the efficacy of GON-injection as first-line prophylactic therapy in episodic cluster headache, by showing that GON-injection decreases the mean total dose of verapamil needed during the…